Altogether, our data indicate that one of the molecular mechanisms by which Endocan affects GBM is binding to PDGFRA and subsequent activation of the downstream signaling pathways in tumor cells adjacent to VE cells in the microvasculature proliferation area. The gene discussed is ESM1; the disease is neoplasm.